Document:WHO WHO - Guidance for best practices for clinical trials 2024
From GxPlex
| Document information | |
|---|---|
| Reference | WHO WHO - Guidance for
best practices for clinical trials 2024 |
| Validity area | WHO |
| Scope(s) | G |
| Document name | WHO - Guidance for
best practices for clinical trials |
| Version / Revision | 2024 |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | WHO - Guidance for best practices for clinical trials |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Scope | Document part | Language | Preview | |
|---|---|---|---|---|
| WHO WHO - Guidance for best practices for clinical trials 2024 1.1 - Clinical Research | G | 1.1 - Clinical Research | EN | […] Clinical research is indispensable for resolving public health challenges. Clinical research studies can be thought of as spanning five generic ar… |
| WHO WHO - Guidance for best practices for clinical trials 2024 1.1 - NIS | G | 1.1 - NIS | EN | [...] Non-interventional studies are observational in nature (hence sometimes known as observational studies), in which health outcomes are typically … |
| WHO WHO - Guidance for best practices for clinical trials 2024 1.1 - Platform, basket and umbrella trials | G | 1.1 - Platform, basket and umbrella trials | EN | [...] Platform, basket and umbrella trials all use master protocols (15–18) which allow simultaneous evaluation of multiple interventions within the … |
| WHO WHO - Guidance for best practices for clinical trials 2024 1.4 | G | 1.4 | EN | 1.4 Persistent challenges to clinical trial enablement There is an urgent need to avoid wasteful procedures and make clinical trials more efficient so… |
| WHO WHO - Guidance for best practices for clinical trials 2024 2.1.3 | G | 2.1.3 | EN | […] Specific examples of populations that have typically been excluded from clinical trials (either explicitly or by implicit exclusion) include pregn… |
| WHO WHO - Guidance for best practices for clinical trials 2024 2.1.8 | G | 2.1.8 | EN | 2.1.8 Proportionate, efficient and reliable capture of data
[...] Disproportionate data collection wastes time and resources. It places an unnecessary… |
| WHO WHO - Guidance for best practices for clinical trials 2024 2.4 | G | 2.4 | EN | 2.4 Good clinical trials are designed to be feasible for their context
[…] Clinical trials should be tailored to be practicable given the available in… |
| WHO WHO - Guidance for best practices for clinical trials 2024 2.5 | G | 2.5 | EN | 2.5 Good clinical trials manage quality effectively and efficiently The design and conduct of a high-quality trial require competent decision-making … |
| WHO WHO - Guidance for best practices for clinical trials 2024 3.2.4 | G | 3.2.4 | EN | 3.2.4 Training and mentoring Investment in education and training is required in all regions through accessible (practically and financially) fit-for-… |
| WHO WHO - Guidance for best practices for clinical trials 2024 Annex 2 2.5 | G | Annex 2 2.5 | EN | A2.2.5 Protecting research participants Researchers should allocate adequate time and resources for measures and materials to obtain properly informed… |
